Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia

Authors

Gina Keiffer, Thomas Jefferson UniversityFollow
Zach French, Thomas Jefferson UniversityFollow
Lindsay Wilde, Thomas Jefferson UniversityFollow
Joanne Filicko-O'Hara, Thomas Jefferson UniversityFollow
Usama Gergis, Thomas Jefferson UniversityFollow
Adam Binder, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

9-18-2020

Comments

This article is the author’s final published version in Frontiers in Oncology, Volume 10, September 2020, Article number 562625.

The published version is available at https://doi.org/10.3389/fonc.2020.562625. Copyright © Keiffer et al.

Abstract

While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.

Recommended Citation

Keiffer, Gina; French, Zach; Wilde, Lindsay; Filicko-O'Hara, Joanne; Gergis, Usama; and Binder, Adam, "Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia" (2020). Department of Medicine Faculty Papers. Paper 278.
https://jdc.jefferson.edu/medfp/278

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

33072589

Language

English